Deutsche Biotech-Unternehmen und ihre Innovationsfähigkeit im internationalen 
Vergleich: Eine institutionentheoretische Analyse

Lange, Knut Stefan Garrit

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学位論文

Deutsche Biotech-Unternehmen und ihre Innovationsfähigkeit im internationalen Vergleich: Eine institutionentheoretische Analyse

MPS-Authors

/persons/resource/persons41234

Lange, Knut Stefan Garrit
Wissenschaft, Technik und Innovationssysteme, MPI for the Study of Societies, Max Planck Society;

External Resource

http://irs.ub.rug.nl/ppn/292008961
(全文テキスト（全般）)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

mpifg_diss06_Lange.pdf
(全文テキスト（全般）), 2MB

付随資料 (公開)

There is no public supplementary material available

引用

Lange, K. S. G. (2006). Deutsche Biotech-Unternehmen und ihre Innovationsfähigkeit im internationalen Vergleich: Eine institutionentheoretische Analyse. PhD Thesis, University of Groningen, Groningen.

引用: https://hdl.handle.net/11858/00-001M-0000-0012-4ACF-2

要旨

Summary
1. Introduction
In the mid-1990s, legal changes and policy initiatives in Germany led to the rapid emergence of a biotechnology industry. Initially, German biotech companies focused on the market segment of platform technologies, characterized by incremental innovations. In recent years however, many companies have shifted their strategic focus on the market
segment of therapeutics, characterized by radical innovations. Since an active involvement in such a segment is untypical for German companies the central research question of this thesis was, if the German institutional framework allowed biotech companies to be internationally competitive in a radical-innovative market segment. The findings are particularly relevant for the literatures on “Varieties of Capitalism”, “National Innovation Systems” and for the sociology of technology. The British and the US biotech industry served as a comparison for the validation of the German case study.